CUPR Stock Forecast 2026-2027 - Cuprina Holdings (Cayman) Ltd. Price Targets & Predictions

Ticker Nerd rank

CUPR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cuprina Holdings (Cayman) Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026

4 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

93

Issuance

26

Revisions

25

Volatility

23

Momentum

20

Accruals

10

Growth

8

Value

6

Quality

6

Size (93): Smaller than most of the companies we track.

Quality (6): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CUPR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CUPR, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CUPR appears on the weeks it earns a place.

Estimates

CUPR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Cuprina Holdings (Cayman) Ltd. (CUPR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: —
Price / sales: 91.4×
Price / book: 1.1×
EV / EBITDA: −1.0×

Growth & margins

Revenue growth (YoY): 267.4%
Earnings growth (YoY): —
Gross margin: —
Operating margin: −10568.3%
Net margin: −1.3%

Returns & dividend

Return on equity: −1569.1%
Return on assets: −58.9%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cuprina Holdings (Cayman) Ltd. (CUPR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Cuprina Holdings (Cayman) Ltd. has a market value of $4.6M and an enterprise value of $3.8M.
Shares outstanding: 2.7M.
Cuprina Holdings (Cayman) Ltd. employs 10 people.

market figures as at 18 Sept 2026

Data provided by Twelve Data

Peers

CUPR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies

Company	Market cap	TKN rank
CUPRCuprina Holdings (Cayman) Ltd.	$4.6M	4
LUCYInnovative Eyewear, Inc.	$8.2M	20
RGNTRegentis Biomaterials Ltd.	$12.7M	8
BNGOBionano Genomics, Inc.	$20.4M	78
RVPRetractable Technologies, Inc.	$21.5M	60
FEMYFemasys, Inc.	$21.7M	43
NXGLNexGel, Inc.	$3.3M	12

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cuprina Holdings (Cayman) Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CUPR news & analysis

Cuprina Holdings (Cayman) Limited Announces Closing of Public Offering

GlobeNewsWire · 18 Sept 2026neutral

Cuprina Holdings (Cayman) Limited announced the closing of its public offering of 4,322,489 Class A Ordinary Shares at $1.15 per share, generating approximately $4.97 million in gross proceeds to the Company before underwriting discounts and offering expenses.

Why it matters — CUPR watchers may monitor this capital raise as it provides the Company with additional funds to support its operations across its biomedical product sectors.

FAQ

Frequently asked questions about CUPR stock

How does Ticker Nerd's model rank CUPR?

As at 19 Sept 2026, Cuprina Holdings (Cayman) Ltd. ranks 4 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).

What is the CUPR stock forecast for 2030?

No analyst covering Cuprina Holdings (Cayman) Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CUPR are extrapolating price history, which says nothing about the business.

What does Cuprina Holdings (Cayman) Ltd. do?

Cuprina Holdings (Cayman) Limited is a biomedical and biotechnology company focused on developing and commercializing products for chronic wound management, infertility, medical waste recycling, and cosmeceuticals. The company’s product portfolio includes medical-grade sterile blowfly larvae bio-dressings used for biological debridement in wound care, alongside other specialty wound treatment solutions and biomaterial-based products.

What is the latest news on CUPR?

The most recent item we track (GlobeNewsWire, 18 Sept 2026): "Cuprina Holdings (Cayman) Limited Announces Closing of Public Offering". Cuprina Holdings (Cayman) Limited announced the closing of its public offering of 4,322,489 Class A Ordinary Shares at $1.15 per share, generating approximately $4.97 million in gross proceeds to the Company before underwriting discounts and offering expenses.

Company

About Cuprina Holdings (Cayman) Ltd.

Cuprina Holdings (Cayman) Limited is a biomedical and biotechnology company focused on developing and commercializing products for chronic wound management, infertility, medical waste recycling, and cosmeceuticals. The company’s product portfolio includes medical-grade sterile blowfly larvae bio-dressings used for biological debridement in wound care, alongside other specialty wound treatment solutions and biomaterial-based products. Cuprina also works with healthcare and wellness applications that combine clinical utility with nature-derived or sustainable inputs. Based in Singapore and incorporated in the Cayman Islands, Cuprina Holdings (Cayman) Limited serves markets in medical devices, wound care, and health and beauty, positioning itself as a niche participant in specialty biomedical products.

CEO Mr. Yong Qi Quek · 10 employees · Singapore · https://www.cuprina.com.sg